due to the slow recruitment of patients & staffing shortages/turnover within study sites related to #COVID19
AddexPharma terminates Phase 2b/3 study o... - Cure Parkinson's
AddexPharma terminates Phase 2b/3 study of Dipraglurant in dyskinesia-associated with Parkinsons - due to the slow recruitment of patients
1 Reply
•
Covid has wrought havoc on clinical trials.
Not what you're looking for?
You may also like...
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
LRRK2-associated #Parkinsons
https://twitter.com/ScienceofPD/status/1522601517542514689...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
trial-sites-for-the-phase-3-study-of-buntanetap-for-the-treatment-of-parkinsons-disease-301741593.ht
Free Webinar: “Zhittya's Parkinson's Disease Research Study: 6-Month Patient Follow-Up Report”
will report on the status of the first Parkinson's disease patients dosed with FGF-1 back in May...
The \"UP-study\" phase 2 trial of UDCA Co funded by Cure Parkinson's led by Prof Oliver Bandmann
\\"UP-study\\" phase 2 trial of UDCA Co funded by Cure Parkinson's led by Prof Oliver Bandmann...
Related Posts
Active recruitment for stem cell trial
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE- AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
- Unsuccessful evaluation of curcumin as add-on therapy in patients with Parkinson's disease, 9 months long, low dose 80 mg/day study
- Vibrating Gloves for Parkinson's Disease
